



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 29th January, 2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. 29th January, 2019

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. 29th January, 2019 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results for the quarter and Nine Month ended on 31st December, 2018.

Please find enclosed Unaudited Standalone and Consolidated Financial Results for the quarter and Nine Month ended on 31st December, 2018 along with the Limited Review Reports of the Auditors.

The meeting of the Board of Directors commenced at 11:45 am. and concluded at 15:20 pm.

This is for your information and record.

Thanking You.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

Encl: a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED (Formerly Known as Eris Lifesciences Private Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the Quarter and Nine Months ended December 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J. Shah".

Gaurav J. Shah
Partner
(Membership No. 35701)

Ahmedabad, January 29, 2019



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

Particulars	[Rs. in Million except per share data]					
	For Quarter Ended			For Nine Months Ended		For Year Ended
	December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
Revenue from Operations						
Sale of products	2,267.61	2,370.74	1,806.71	6,865.16	5,423.68	7,323.36
Other operating income	40.42	37.37	15.37	115.93	241.59	282.65
Total Revenue from Operations	2,308.03	2,408.11	1,822.08	6,981.09	5,665.27	7,606.01
Other Income	101.54	62.39	60.16	208.99	200.21	282.23
Total Income	2,409.57	2,470.50	1,882.24	7,190.08	5,865.48	7,888.24
Expenses						
Cost of materials consumed	199.01	133.29	114.41	466.44	345.55	470.79
Purchase of stock-in-trade	246.15	213.11	320.59	580.83	481.65	648.90
Changes in inventories of Finished goods, Work-in-Progress and Stock-in-trade	(107.75)	6.19	(171.46)	(27.24)	(29.19)	(35.43)
Employee Benefits Expense	416.62	405.84	352.25	1,257.28	951.54	1,308.45
Finance Costs	50.94	62.40	27.06	184.10	27.06	104.29
Depreciation and Amortisation Expense	83.93	70.75	56.09	215.54	140.23	217.92
Other Expenses	647.99	679.04	414.13	1,986.39	1,478.50	2,054.43
Total Expenses	1,536.89	1,570.62	1,113.07	4,663.34	3,395.34	4,769.35
Profit before Tax	872.68	899.88	769.17	2,526.74	2,470.14	3,118.89
Tax Expense						
Current Tax	191.94	198.35	168.88	556.50	539.03	679.46
Deferred Tax	(108.03)	(138.31)	(138.86)	(359.41)	(430.48)	(497.12)
Total Tax Expense	83.91	60.04	30.02	197.09	108.55	182.34
Net Profit for the period	788.77	839.84	739.15	2,329.65	2,361.59	2,936.55
Other Comprehensive Income	0.33	0.99	(1.22)	0.99	(3.68)	(0.73)
Items that will not be reclassified to profit or loss	0.51	1.52	(1.87)	1.53	(5.63)	(1.12)
Income tax relating to items that will not be reclassified to profit or loss	(0.18)	(0.53)	0.65	(0.54)	1.95	0.39
Total Comprehensive Income	789.10	840.83	737.93	2,330.64	2,357.91	2,935.82
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.52	137.52	137.50	137.52	137.50	137.50
Other Equity						8,544.29
Earnings Per Share (of Rs. 1 each) (not annualised) :						
Basic	5.74	6.10	5.38	16.94	17.18	21.36
Diluted	5.74	6.10	5.38	16.93	17.18	21.36
See accompanying notes to the financial results						



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
 Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000
 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in
 CIN: L24232GJ2007PLC049867

